• January 19, 2007
    NEW YORK--Pfizer Animal Health, a division of Pfizer Inc (NYSE: PFE) today announced the completion of its acquisition of Embrex, Inc. (Nasdaq: EMBX), an international agricultural biotechnology company known for its Inovoject(R) vaccine-delivery systems. Completion followed the Embrex shareholder meeting today at which Embrex shareholders approved the merger. The transaction has an aggregate equity purchase price of approximately $155 millionmore...
  • December 12, 2006
    RESEARCH TRIANGLE PARK, N.C.--Embrex(R), Inc., The In Ovo Company(R), (Nasdaq: EMBX) announced that a special meeting of its shareholders will be held on January 19, 2007 at 9:00 a.m. local time at its corporate headquarters at 1040 Swabia Court, Durham, North Carolina 27703 to consider and vote upon a proposal to approve and adopt the Agreement and Plan of Merger dated as of November 14, 2006, among Embrex, Inc., Pfizer Inc. and Eagle Mergermore...
  • November 15, 2006
    NEW YORK & RESEARCH TRIANGLE PARK, N.C.--Pfizer Animal Health, a division of Pfizer Inc (NYSE: PFE) has agreed to acquire Embrex, Inc. (NASDAQ: EMBX), an international agricultural biotechnology company known for its Inovoject® vaccine-delivery systems, the companies announced today. Under the terms of the agreement, Pfizer will acquire through a merger 100 percent of the equity of Embrex for $17 per share in cash, makingmore...